Skip to main content
. 2001 Feb 13;98(5):2652–2657. doi: 10.1073/pnas.041603898

Figure 2.

Figure 2

(A–D) NCX-1000 (15 mg/kg) reduces IL-1β, IL-18, and IFN-γ release in Con A-treated mice. Data points represent the mean ± SE for five mice/group. *, P < 0.01 versus Con A alone. (E) Reverse transcription–PCR analysis of hypoxanthine-guanine phosphoribosyl transferase (HPRT), Fas, FasL, IL-1β, IL-18, and IFN-γ mRNA transcripts on liver lysates. Lane 1, control; lane 2, 8 h after Con A injection; lane 3, 24 h after Con A injection; lane 4: Con A plus UDCA, 15 mg/kg; lane 5, Con A plus NCX-1000, 15 mg/kg.